Display options
Cite
Trincavelli ML, Da Pozzo E, Ciampi O, et al. Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study. Int J Mol Sci. 2013;14(2):2258-81doi: 10.3390/ijms14022258.
Trincavelli, M. L., Da Pozzo, E., Ciampi, O., Cuboni, S., Daniele, S., Abbracchio, M. P., & Martini, C. (2013). Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study. International journal of molecular sciences, 14(2), 2258-81. https://doi.org/10.3390/ijms14022258
Trincavelli, Maria Letizia, et al. "Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study." International journal of molecular sciences vol. 14,2 (2013): 2258-81. doi: https://doi.org/10.3390/ijms14022258
Trincavelli ML, Da Pozzo E, Ciampi O, Cuboni S, Daniele S, Abbracchio MP, Martini C. Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study. Int J Mol Sci. 2013 Jan 24;14(2):2258-81. doi: 10.3390/ijms14022258. PMID: 23348925; PMCID: PMC3587987.
Copy Download .nbib Format: NLM
Share it on

Int J Mol Sci. 2013 Jan 24;14(2):2258-81. doi: 10.3390/ijms14022258.

Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study.

International journal of molecular sciences

Maria Letizia Trincavelli, Eleonora Da Pozzo, Osele Ciampi, Serena Cuboni, Simona Daniele, Maria Pia Abbracchio, Claudia Martini

Affiliations

  1. Department of Pharmacy, University of Pisa, Pisa 56126, Italy. [email protected].

PMID: 23348925 PMCID: PMC3587987 DOI: 10.3390/ijms14022258

Abstract

In endothelial cells, erythropoietin receptors (EPORs) mediate the protective, proliferative and angiogenic effects of EPO and its analogues, which act as EPOR agonists. Because hormonal receptors undergo functional changes upon chronic exposure to agonists and because erythropoiesis-stimulating agents (ESAs) are used for the long-term treatment of anemia, it is critical to determine the mechanism by which EPOR responsiveness is regulated at the vascular level after prolonged exposure to ESAs. Here, we investigated EPOR desensitization/resensitization in human umbilical vein endothelial cells (HUVECs) upon exposure to three ESAs with different pharmacokinetic profiles, epoetin alpha (EPOα), darbepoetin alpha (DarbEPO) and continuous EPOR activator (CERA). These agonists all induced activation of the transcription factor STAT-5, which is a component of the intracellular pathway associated with EPORs. STAT-5 activation occurred with either monophasic or biphasic kinetics for EPOα/DarbEPO and CERA, respectively. ESAs, likely through activation of the STAT-5 pathway, induced endothelial cell proliferation and stimulated angiogenesis in vitro, demonstrating a functional role for epoetins on endothelial cells. All epoetins induced EPOR desensitization with more rapid kinetics for CERA compared to EPOα and DarbEPO. However, the recovery of receptor responsiveness was strictly dependent on the type of epoetin, the agonist concentration and the time of exposure to the agonist. EPOR resensitization occurred with more rapid kinetics after exposure to low epoetin concentrations for a short period of desensitization. When the highest concentration of agonists was tested, the recovery of receptor responsiveness was more rapid with CERA compared to EPOα and was completely absent with DarbEPO. Our results demonstrate that these three ESAs regulate EPOR resensitization by very different mechanisms and that both the type of molecule and the length of EPOR stimulation are factors that are critical for the control of EPOR functioning in endothelial cells. The differences observed in receptor resensitization after stimulation with the structurally different ESAs are most likely due different control mechanisms of receptor turnover at the intracellular level.

References

  1. J Biol Chem. 1986 Mar 5;261(7):3116-21 - PubMed
  2. Cell. 1995 Mar 10;80(5):729-38 - PubMed
  3. FEBS Lett. 1998 May 8;427(2):164-70 - PubMed
  4. Clin J Am Soc Nephrol. 2008 Jan;3(1):200-7 - PubMed
  5. Thromb Res. 2002 Jan 15;105(2):161-4 - PubMed
  6. Biol Res. 2009;42(3):377-89 - PubMed
  7. Peptides. 2008 Aug;29(8):1451-5 - PubMed
  8. Biopharm Drug Dispos. 2011 Jul;32(5):276-88 - PubMed
  9. Kidney Int. 1993 Jul;44(1):182-90 - PubMed
  10. Exp Hematol. 2008 Dec;36(12):1573-84 - PubMed
  11. Blood. 2009 May 21;113(21):5287-97 - PubMed
  12. Kidney Int. 1996 Aug;50(2):481-8 - PubMed
  13. Kidney Int. 2006 Jul;70(2):246-50 - PubMed
  14. J Cardiovasc Pharmacol. 2007 Jun;49(6):337-45 - PubMed
  15. Eur Heart J. 2007 Aug;28(16):2018-27 - PubMed
  16. Nephron. 2000 Apr;84(4):305-11 - PubMed
  17. Genes Dev. 1996 Jan 15;10(2):154-64 - PubMed
  18. J Thromb Thrombolysis. 2008 Dec;26(3):183-7 - PubMed
  19. Kidney Int. 2000 May;57(5):1895-904 - PubMed
  20. Br J Pharmacol. 2010 Aug;160(8):2085-96 - PubMed
  21. Blood. 2010 Feb 18;115(7):1453-60 - PubMed
  22. FEBS Lett. 2002 May 8;518(1-3):189-94 - PubMed
  23. Blood. 1999 Apr 15;93(8):2627-36 - PubMed
  24. Clin Appl Thromb Hemost. 2002 Jan;8(1):77-84 - PubMed
  25. Nephrol Dial Transplant. 2001;16 Suppl 3:3-13 - PubMed
  26. Thromb Haemost. 2002 Oct;88(4):678-85 - PubMed
  27. J Biol Chem. 1996 Dec 13;271(50):32430-7 - PubMed
  28. Blood. 2003 Aug 15;102(4):1340-6 - PubMed
  29. Am J Physiol Heart Circ Physiol. 2005 Sep;289(3):H1106-14 - PubMed
  30. Trends Endocrinol Metab. 1999 Dec;10(1):18-23 - PubMed
  31. J Biol Chem. 2011 Feb 25;286(8):6449-57 - PubMed
  32. Am J Chin Med. 2009;37(4):747-57 - PubMed
  33. Blood. 2002 Oct 1;100(7):2279-88 - PubMed
  34. J Biol Chem. 2000 Jun 16;275(24):18375-81 - PubMed
  35. Eur J Clin Invest. 2008 Jul;38(7):457-61 - PubMed
  36. Pharmacology. 2008;81(1):63-9 - PubMed
  37. J Cell Physiol. 2011 Dec;226(12):3330-9 - PubMed
  38. Clin Appl Thromb Hemost. 2003 Oct;9(4):349-52 - PubMed
  39. Int J Clin Exp Pathol. 2011;4(8):765-74 - PubMed
  40. Blood. 2005 Jan 15;105(2):600-8 - PubMed
  41. Blood. 2007 Jun 15;109(12):5215-22 - PubMed
  42. Blood. 1987 May;69(5):1485-90 - PubMed
  43. Circulation. 2004 Aug 24;110(8):1006-12 - PubMed
  44. Thromb Res. 2007;120(6):797-803 - PubMed
  45. Cytokine. 2010 Aug;51(2):113-8 - PubMed
  46. Heart. 2011 Oct;97(19):1537-9 - PubMed
  47. Heart Vessels. 2012 Jan;27(1):79-88 - PubMed
  48. J Biol Chem. 2006 Jan 27;281(4):2024-32 - PubMed
  49. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3974-8 - PubMed
  50. Cardiovasc Drugs Ther. 2012 Oct;26(5):409-16 - PubMed
  51. Kidney Int. 2001 Aug;60(2):741-7 - PubMed
  52. Proc Natl Acad Sci U S A. 1990 Sep;87(18):6934-8 - PubMed
  53. Clin J Am Soc Nephrol. 2006 Nov;1(6):1211-5 - PubMed
  54. BMC Nephrol. 2011 Dec 12;12:67 - PubMed
  55. Neuroscience. 1997 Jan;76(1):105-16 - PubMed
  56. Curr Hematol Rep. 2005 Nov;4(6):436-40 - PubMed
  57. Chembiochem. 2008 Mar 25;9(5):723-7 - PubMed
  58. Exp Hematol. 2004 Dec;32(12):1146-55 - PubMed
  59. J Immunol. 2000 Dec 1;165(11):6372-80 - PubMed
  60. Int J Oncol. 2012 Apr;40(4):1230-7 - PubMed
  61. Expert Rev Mol Med. 2008 Dec 01;10:e36 - PubMed
  62. J Korean Med Sci. 2012 Sep;27(9):1073-8 - PubMed
  63. Kidney Int. 1995 Mar;47(3):740-5 - PubMed
  64. Blood. 1953 Apr;8(4):349-57 - PubMed

Publication Types